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Any Defining Role 
of Mast Cell or 
Mast Cell Density in 
Oral Squamous Cell 
Carcinoma?
Dear Sir,
I read an article by Zaidi et al. titled to “A study on assessment 
of mast cell (MCs) in oral squamous cell carcinoma (OSCC)” 
with great interest.[1] We are concerned about their meandering 
conclusion presuming close association between OSCC 
development and MC. Since the role of MCs in the tumor 
stroma has been very controversial so far, it needs further 
clarification.	Furthermore,	my	interest	in	this	study	is	that	we	
have recently demonstrated human MC-mediated cytotoxicity 
against different human tumor cells in vitro.[2,3] Here, we want 
to emphasize anti-tumor effects of MC in the light of recent 
literature	and	our	findings	as	well.
Contrary to the results of this study;[1] high MC density (MCD) 
in OSCC is found to be associated with a greater survival.[4] 
Another study demonstrated no correlation between MCD 
with clinical and microscopic characteristics of OSCC.[5] 
In other tumors, increased MCD is not always associated with 
bad prognosis and/or increased metastasis too. It may also 
indicate a good prognosis and better survival such as in soft 
tissue sarcomas, pulmonary adenocarcinoma and colorectal 
cancer.[6,7] Moreover, a recent study also showed that MC 
accumulation was suggested to inhibit the proliferation and 
the dissemination of the gastric carcinoma.[8] Thus; these 
conflicting	 results	 in	 the	 literature	may	 raise	 the	 question	
about biopsy timing in the studies. And what we see in the 
specimen	 could	 be	 reflecting	 late	 or	 early	 stages	 of	 tumor	
development and surely in the beginning we could see different 
subpopulations in tumor stroma. Besides the timing of the 
study, variations in tumor type and methods also may cause 
perplexing results.[2,3]	So	could	MCs	have	a	specific	role	 in	
tumor development or progression?
Availability	of	MCs	in	inflamed	tissues	and	physiologically	
around healing tissue, scars and ovulation areas raise also the 
question about MC really being an active player or an innocent 
passerby?	In	fact,	MCs	just	might	be	a	reflection	of	generalized	
inflammatory	reaction	of	the	immune	system.	Some	researchers	
think that the MCs may represent reactive cell types involving 
in the pathophysiology of the host reaction, for example, 
in early gastric or breast cancer.[9] Or this tumor-induced 
inflammatory	reaction	including	macrophages	and	fibroblasts	
in the stroma could establish a local microenvironment 
favoring tumor progression via angiogenesis such as in 
melanoma, and in here some of the angiogenic factors may 
stimulate MC migration as well.[10] Thus, observing MCD in 
only tumor tissue with bad/good prognosis on histopathological 
specimens	seems	to	be	insufficient	to	explain	the	real	role	of	
MC in that tumor stroma.
In this study,[1] MCs in the tumor-surrounding tissue exhibited 
signs of activation by releasing their mediators (degranulation). 
MC mediators mediate different functions, and the coexistence 
of	MCs	besides	other	inflammatory	cells	contributes	to	tissue	
homeostasis.	Since	mediators	have	been	shown	to	influence	
various aspects of tumor biology, the net effect of MCs in the 
tumor	progression	 is	difficult	 to	evaluate.	For	 instance	 in	a	
study,	tryptase	was	thought	to	be	a	mediator	causing	fibrosis,	
thus limiting tumor invasion, as well as an angiogenic, possibly 
contributing to a better chemotherapy response of tumor 
cells.	Thus,	both	fibrosis	and	angiogenesis	mediated	by	MC	
tryptase may contribute the overall better survival in advanced 
ovarian cancer.[11] Furthermore, chymase induces apoptosis in 
different types of cells including endothelial cells involved 
in the angiogenesis, tryptase is known to be an angiogenic 
agent. Thus, mediators of MCs are able to stimulate as well 
as inhibit angiogenesis thru their mediators e.g. tryptase/
heparin versus protamine/platelet factor 4. Furthermore, 
even some of the mediators such as tryptase, tumor necrosis 
factor alpha (TNF-α), chymase and cathepsin G are held 
responsible from both actions.[12-14] Perplexingly, degradation 
of MC cytokines including TNF-α immediately after released 
was lately demonstrated. Chymase and cathepsin G were 
identified	as	the	likely	culprits	that	digest	these	cytokines.[15] 
It may not be clear what reactions occur between stimulators 
and inhibitors and what the proportional contribution of the 
respective mediators in tumor development.
Although some still postulate MCs to be enhancers of tumor 
development, especially through their effects on angiogenesis; 
increasing clinic and laboratory data also indicates that 
MCs could inhibit tumor growth.[1-3] Tumor-induced 
angiogenesis (neoangiogenesis) was found to be associated 
with a greater survival in various tumors and was also 
thought to be related with a better response to chemotherapy 
in advanced ovarian cancer.[11] Neoplastic angiogenesis 
is a more complex process than what described, and the 
mechanisms	plus	its	importance	are	not	clarified.	Noticeably,	
most	of	the	angiogenesis‑stimulating	factors	e.g.	the	fibroblast	
growth factor, platelet-derived endothelial cell growth factor, 
transforming growth factor, vascular endothelial growth factor, 
etc., have been also shown to be produced by tumor itself 
or stromal cells rather than MCs. Nonetheless, in addition 
to the capability of MCs to kill tumor and endothelial cells, 
recent	studies	also	found	no	significant	association	between	
angiogenesis and MCD in human cancers such as in ovarian/
renal cancer, even with non-small cell lung carcinomas.[6,7,16-18] 
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Earlier	 studies	 showed	 no	 significant	 difference	 between	
MC‑deficient	 and	 sufficient	mice	 for	 the	 angiogenesis.[19] 
In a study evaluating growth of pulmonary metastases of B16 
melanoma;	 lung	metastases	were	 significantly	decreased	 in	
controls, compared to an MC-free animal, W/Wv mice.[20] 
In another study carried out with B16 melanoma cells in two 
strains	of	MC‑deficient	mice	suggested	that	the	MC	dependence	
of antitumor resistance.[21] In vitro, MC-mediated apoptosis of 
endothelial cells was also shown to be contrary to MC-induced 
angiogenesis hypothesis.[22] Although TNF-α, tryptase and 
cathepsin G are stated as the angiogenesis-stimulating factors 
of MC; especially TNF-α and cathepsin G are also believed 
to mediate MC-mediated cytotoxicity against murine tumor 
and target cells.[23] Furthermore, degradation of MC mediators 
immediately after released was lately demonstrated.[15] If MC 
always induces angiogenesis, how do authors explain the 
lack of correlation between angiogenesis and systemic MC 
diseases?
Neoplastic angiogenesis is a complex process, including 
macrophages, eosinophils, stromal, endothelial progenitor as 
well as tumor cells.[12-14] Moreover, some hold macrophage/
tumor/endothelial progenitor or stromal cells responsible 
from the neoplastic angiogenesis.[24]	A	significant	correlation	
between prognosis, tumor-associated macrophages, and 
neoangiogenesis was shown in several reports of renal cell 
carcinomas.[25] It is also mediated by different kinds of 
mediators released from different cells including tumor as 
well as MCs. Essentially heparin-like molecules; interleukin-8, 
stem	cell	factor,	basic	fibroblast	growth	factor,	transforming	
growth factor beta, angiopoietins and histamine were 
believed to be responsible from neovascularization.[26] In 
the neoplastic angiogenesis, individual angiogenic factor 
expression characteristics of tumors are also important, 
for example, caveolin-1, hypoxia-inducible factor-1α, and 
matrix metalloproteinase expressions by tumor cells. Such 
as in melanomas, for example, interleukin-3 and substance 
P expressions should also be considered. Substance P also 
is known to potentiate neoangiogenesis.[27] Furthermore; in 
clinical specimens of OSCC development, several studies 
provided data on the role of concomitant expression of 
stromelysin 3 in tumor tissue. Another study also suggested 
that stromelysin 3 expression in oral hyperplastic/dysplastic 
lesions is associated with progression of phenotypic alterations 
acquired early during the malignant transformation pathway 
of oral epithelium. And this study implicates its role not only 
in angiogenesis and invasion but also in tumorigenesis.[28,29] 
In addition, the importance of vascular endothelial growth 
factor,	 basic	 fibroblast	 growth	 factor,	 and	 platelet‑derived	
endothelial growth factor expressions in OSCC has been 
recently reported.[30] Angiogenic cooperation was also reported 
in a tumor stroma between different mediators such as 
prostaglandin-F2-alpha, vascular endothelial growth 
factor, and thymidine phosphorylase.[4,31] As one imagines, 
in this chaotic environment, the MC’s genuine role on 
tumor‑associated	angiogenesis	is	very	difficult	to	define.	This	
tumor‑induced	inflammatory	reaction,	including	macrophages	
and	 fibroblasts	 could	 establish	 a	 local	microenvironment	
favoring tumor progression via angiogenesis; and some of the 
angiogenic factors may stimulate MC migration.[10,32] MCD, 
neoangiogenesis	and	their	significance	in	tumor	development	
as well as in prognosis are lately discussed by us with a 
different perspective.[12-14]
Like Zaidi et al., MCs have been thought by some researchers 
as a new target in the treatment of tumors through the 
selective inhibition of angiogenesis, tissue remodeling and 
tumor promoting molecules.[1] Anti-angiogenic strategies 
have recently become an important therapeutic modality for 
tumors.[33] Nevertheless, beside MCs, myeloid cells, monocytes 
and vascular leukocytes have recently been shown as new 
targets in the regulation of tumor-associated angiogenesis. 
For instance: Anti-angiogenic effect of tranilast occurs not 
by simply MC stabilization rather via its overall inhibiting 
effect	on	macrophage	cytokine	release,	fibroblast,	and	smooth	
muscle proliferation.[33] In the targeted therapy age,[34] studies 
of the targeting MCs’ role in cancer might have direct clinical 
consequences and should be further elucidated via utilizing 
histopathological and complex biological models.[35-37]
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